Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLDXNASDAQ:INVANASDAQ:NVAXNASDAQ:RIGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$20.50-1.5%$19.87$14.40▼$47.00$1.36B1.33938,122 shs1.56 million shsINVAInnoviva$21.00-2.1%$19.40$15.95▼$22.00$1.32B0.37675,409 shs1.22 million shsNVAXNovavax$6.41+1.7%$6.74$5.01▼$17.81$1.04B2.816.36 million shs4.82 million shsRIGLRigel Pharmaceuticals$18.93-2.2%$19.28$7.48▼$29.82$338.28M1.29220,726 shs304,828 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics0.00%-3.57%+0.74%-1.35%-41.88%INVAInnoviva0.00%-3.18%+10.70%+21.18%+32.08%NVAXNovavax0.00%-7.64%-11.59%-16.64%-54.21%RIGLRigel Pharmaceuticals0.00%-7.75%-0.11%-7.84%+99.26%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLDXCelldex Therapeutics2.7593 of 5 stars4.43.00.00.02.80.00.0INVAInnoviva4.242 of 5 stars3.50.00.04.23.51.71.9NVAXNovavax4.3897 of 5 stars3.12.00.04.71.30.83.1RIGLRigel Pharmaceuticals3.5291 of 5 stars3.22.00.00.02.71.73.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLDXCelldex Therapeutics 2.89Moderate Buy$50.11144.44% UpsideINVAInnoviva 3.00Buy$55.00161.90% UpsideNVAXNovavax 2.29Hold$17.00165.21% UpsideRIGLRigel Pharmaceuticals 2.40Hold$36.4092.29% UpsideCurrent Analyst Ratings BreakdownLatest RIGL, INVA, NVAX, and CLDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025NVAXNovavaxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSell$6.006/13/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.005/19/2025NVAXNovavaxB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/9/2025CLDXCelldex TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$44.00 ➝ $38.005/9/2025CLDXCelldex TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$36.00 ➝ $31.005/9/2025CLDXCelldex TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$46.00 ➝ $43.005/9/2025NVAXNovavaxJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$9.00 ➝ $7.005/7/2025RIGLRigel PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $23.005/6/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.004/28/2025CLDXCelldex TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$64.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLDXCelldex Therapeutics$7.02M193.84N/AN/A$11.26 per share1.82INVAInnoviva$358.71M3.68$3.43 per share6.13$11.03 per share1.90NVAXNovavax$682.16M1.52N/AN/A($3.89) per share-1.65RIGLRigel Pharmaceuticals$179.28M1.89$1.08 per share17.55$0.19 per share99.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLDXCelldex Therapeutics-$157.86M-$2.70N/AN/AN/A-2,366.07%-23.46%-22.35%8/6/2025 (Estimated)INVAInnoviva$23.39M-$1.01N/A13.55N/A-16.15%15.77%8.41%7/29/2025 (Estimated)NVAXNovavax-$187.50M$2.652.4280.130.0738.14%-115.51%29.99%8/14/2025 (Estimated)RIGLRigel Pharmaceuticals$17.49M$2.079.1418.03N/A18.31%-655.26%24.47%8/5/2025 (Estimated)Latest RIGL, INVA, NVAX, and CLDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CLDXCelldex Therapeutics-$0.75-$0.81-$0.06-$0.81$1.08 million$0.70 million5/8/2025Q1 2025NVAXNovavax$0.71$2.93+$2.22$2.93$204.08 million$666.66 million5/7/2025Q1 2025INVAInnovivaN/A$0.25N/A-$0.74N/A$88.63 million5/6/2025Q1 2025RIGLRigel Pharmaceuticals$0.14$0.63+$0.49$0.63$43.87 million$53.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLDXCelldex TherapeuticsN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLDXCelldex TherapeuticsN/A21.6721.67INVAInnoviva0.402.482.30NVAXNovavaxN/A2.062.03RIGLRigel Pharmaceuticals2.422.202.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLDXCelldex TherapeuticsN/AINVAInnoviva99.12%NVAXNovavax53.04%RIGLRigel Pharmaceuticals66.23%Insider OwnershipCompanyInsider OwnershipCLDXCelldex Therapeutics4.40%INVAInnoviva2.25%NVAXNovavax1.00%RIGLRigel Pharmaceuticals9.04%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLDXCelldex Therapeutics15066.38 million63.46 millionOptionableINVAInnoviva10062.78 million61.36 millionOptionableNVAXNovavax1,990161.97 million160.35 millionOptionableRIGLRigel Pharmaceuticals16017.87 million16.26 millionOptionableRIGL, INVA, NVAX, and CLDX HeadlinesRecent News About These CompaniesRigel Pharmaceuticals (NASDAQ:RIGL) shareholders have earned a 99% return over the last yearJune 21 at 6:53 PM | finance.yahoo.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Stake Boosted by GAMMA Investing LLCJune 21 at 3:18 AM | marketbeat.comRigel Pharmaceuticals' SWOT analysis: promising pipeline drives stock potentialJune 14, 2025 | investing.comAssenagon Asset Management S.A. Buys 112,003 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)June 14, 2025 | marketbeat.comCantor Fitzgerald Weighs in on RIGL FY2026 EarningsJune 10, 2025 | marketbeat.comWellington Management Group LLP Makes New Investment in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)June 8, 2025 | marketbeat.comTwo Sigma Investments LP Makes New $1.03 Million Investment in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)June 6, 2025 | marketbeat.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Sold by Nuveen Asset Management LLCJune 6, 2025 | marketbeat.comMillennium Management LLC Takes $1.19 Million Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)June 5, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Invests $676,000 in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)June 4, 2025 | marketbeat.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Rating of "Hold" from BrokeragesJune 2, 2025 | marketbeat.comSquarepoint Ops LLC Purchases 18,159 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)June 1, 2025 | marketbeat.comTwo Sigma Advisers LP Grows Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)June 1, 2025 | marketbeat.comIs Rigel Pharmaceuticals (RIGL) Stock Undervalued Right Now?May 29, 2025 | zacks.comWall Street Analysts See a 71.97% Upside in Rigel (RIGL): Can the Stock Really Move This High?May 28, 2025 | zacks.comRigel to Present at the Jefferies Global Healthcare ConferenceMay 28, 2025 | prnewswire.comJane Street Group LLC Has $1.05 Million Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)May 24, 2025 | marketbeat.comRigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 CongressMay 22, 2025 | prnewswire.comHere's Why Rigel (RIGL) Is a Great 'Buy the Bottom' Stock NowMay 14, 2025 | zacks.comIs Rigel Pharmaceuticals (RIGL) a Great Value Stock Right Now?May 13, 2025 | zacks.comUpgrade: Analysts Just Made A Captivating Increase To Their Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) ForecastsMay 11, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRIGL, INVA, NVAX, and CLDX Company DescriptionsCelldex Therapeutics NASDAQ:CLDX$20.50 -0.32 (-1.54%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$19.93 -0.57 (-2.78%) As of 06/20/2025 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Innoviva NASDAQ:INVA$21.00 -0.46 (-2.14%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$20.99 -0.01 (-0.05%) As of 06/20/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Novavax NASDAQ:NVAX$6.41 +0.11 (+1.75%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$6.40 0.00 (-0.08%) As of 06/20/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.Rigel Pharmaceuticals NASDAQ:RIGL$18.93 -0.43 (-2.22%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$19.14 +0.21 (+1.11%) As of 06/20/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
